Time | Session |
---|---|
13:30
15:00
|
Renal Cell Carcinoma
TICC - 2F 201BC
|
15:30
17:00
|
Novel Advances (B): Bladder
Jian-Ri LiTaiwan
Moderator
Applying Vision Augmentation in Robotic Surgery: Reality or FictionApplying Vision Augmentation in Robotic Surgery: Reality or Fiction
Seong Il SeoKorea (Republic of)
Moderator
Comparison of Remal Function between Radiofrequency Ablation versus Robot Assisted Laparoscopic Patial Nephrectomy for Small Renal Mass in Elderly PatientsComparison of renal function between radiofrequency ablation versus robot assisted laparoscopic partial nephrectomy for small renal mass in elderly patients
Jiwoong Yu, Seongil Seo
Sungkyunkwan University, Samsung Medical Center
The incidence of small renal masses (SRMs) in patients ≥75 years has increased up to 30-fold [J Urol 2014]. In this age group, treatment should balance cancer control and renal function preservation. Robot-assisted partial nephrectomy (RAPN) and radiofrequency ablation (RFA) are two main options.
RAPN offers excellent cancer control but requires general anesthesia and ischemia, which may pose risks in older patients. RFA is less invasive, avoids vascular clamping, and is often preferred for high-risk patients, as supported by EAU and AUA guidelines.
RFA generally preserves renal function better [Front Oncol 2022], though outcomes vary by technique. At our center, RFA under general anesthesia with wide safety margins may compromise parenchymal preservation.
While both approaches show favorable cancer control, RFA has a slightly higher recurrence rate. Pantelidou et al. reported 6 recurrences in 63 RFA cases vs. 1 in 63 RAPN cases [Cardiovasc Intervent Radiol 2016], and Park et al. reported 2-year recurrence-free survival (RFS) of 95.2% in RFA vs. 100% in RAPN [Eur Radiol 2018]. NCCN guidelines note that RFA may require repeat treatment to match surgical outcomes.
Our institutional matched analysis (63 RAPN vs. 63 RFA) showed RFS of 100% vs. 95.2% (p = 0.029), and immediate eGFR preservation of 91.7% vs. 86.8% [Eur Radiol 2018;28:2979–2985]. A subsequent analysis of older patients presented at AUA 2024 included 137 patients aged ≥75, the rate of ≥25% eGFR decline at one year was 28.6% for RFA vs. 2.0% for RAPN (HR 11.3, p = 0.002), with 4 recurrences in RFA and none in RAPN.
In conclusion, both RFA and RAPN are viable options for elderly patients with small renal masses. RFA is less invasive but may carry a slightly higher risk of recurrence and, depending on institutional technique, some degree of renal function loss. Treatment should be individualized based on tumor anatomy, patient condition, and institutional expertise.
TWTC - 1F Exhibition Hall
|